In recent years, benefiting from the country's further attention to drug quality and pharmaceutical equipment industry, the successive introduction of relevant industrial policies in the pharmaceutical industry, and the growing demand of pharmaceutical enterprises for new construction and upgrading of production lines, the sales of pharmaceutical equipment industry and the performance of related enterprises have been further improved
.
The development direction of the pharmaceutical machine industry is gradually clear, and the concentration may continue to increase (Image source: Pharmaceutical Network)
The development situation of the pharmaceutical equipment industry is good, and the performance of enterprises is eye-catching
In the first half of 2022, the performance of many pharmaceutical equipment enterprises was red, and the revenue of Chutian Technology and Dongfulong both achieved a growth of more than 20%, and the net profit increased
significantly.
Among them, Chutian Technology achieved revenue of about 2.
871 billion yuan in the first half of the year, a year-on-year increase of 20.
04%; The net profit was about 299 million yuan, a year-on-year increase of 26.
74%.
In the first three quarters, Chutian Technology achieved operating income of 4.
495 billion yuan, a year-on-year increase of 22.
06%, net profit attributable to shareholders of listed companies was 463 million yuan, a year-on-year increase of 15.
32%, and earnings per share was 0.
7840 yuan; Dongfulong achieved revenue of 3.
817 billion yuan, net profit attributable to parents of 604 million yuan, and net profit of 566 million yuan, a year-on-year increase of 32.
43%, 8.
29% and 10.
92%
respectively.
While the company's performance is growing, since the beginning of this year, Chutian Technology, Dongfulong and other leading enterprises have also increased investment in R&D and innovation, and are actively expanding production capacity and accelerating internationalization
.
For example, in terms of R&D investment, Chutian Technology's 2022 interim report shows that the company's R&D investment during the reporting period was 232 million yuan, a year-on-year increase of 17.
32%.
According to the company's third quarterly report, the company's R&D investment in the first three quarters was about 375 million yuan, of which nearly 150 million yuan was invested in R&D in the third quarter, which continued to grow
significantly year-on-year.
Dongfulong's R&D investment also increased in the first half of the year, reaching 151 million yuan, a year-on-year increase of 53.
00%.
In addition, in terms of internationalization, recently, a number of local pharmaceutical companies have revealed that a large number of products have been sent to overseas markets, such as Shanghai Lu Xiangyi and many batches of centrifuges exported to Russia and Italy, Changzhou Lili Drying Equipment Co.
, Ltd.
spray dryers sent to Mauritius
.
The development direction of the pharmaceutical equipment industry has gradually become clear
The industry believes that the demand of the downstream pharmaceutical industry will promote the development of the pharmaceutical equipment industry, and higher capacity demand will bring more equipment demand, and the industry will change from cyclical to growth
.
In this process of transformation, the development direction of the pharmaceutical equipment industry has gradually become clear: intelligence, digitalization and greening will become the main trends of industrial development, the demand for overall solutions is increasing, and there is room for import substitution of high-end products; Overseas market expansion is expected to open up the growth ceiling
of domestic enterprises.
In the current situation that the development direction of the pharmaceutical equipment industry has been clear, in fact, many pharmaceutical machinery companies have already begun to accelerate their positive actions
.
For example, on December 8, Xinhua Medical said at the performance meeting that in addition to supplementing working capital, the company's non-public offering funds were used for six projects, including intelligent manufacturing and supporting projects based on flexible processing production lines, and high-end precision minimally invasive surgical instrument production expansion projects, and some of the raised funds have begun to be produced in small batches under existing conditions and generate profits
.
In the post-epidemic era, the introduction of national policies has also brought new development opportunities
for Xinhua medical infection control, clean technology and other products.
In this regard, it said that it will provide advanced and comprehensive product and service solutions in specialized departments such as disinfection supply centers and endoscopy centers, seize market incremental opportunities, and expand the market share
of the company's products.
In addition, on July 13 this year, Dongfulong's 3.
2 billion yuan private placement has also been approved, market analysis said, which will increase the development potential of Dongfulong in capacity construction and process technology, and the company's brand and market share are expected to rise
.
epilogue
In general, the current development direction of the pharmaceutical equipment industry has gradually become clear, and many pharmaceutical equipment companies are also strengthening technological innovation, product updates and other ways to improve their own strength and seize more markets
.
However, it should be noted that due to the overall low degree of production scale and intensification in China's pharmaceutical equipment industry, the technological development and innovation ability of large and small enterprises, and the large difference in technology, the industry expects that the concentration of the pharmaceutical equipment industry in the future will also accelerate, forming a competitive pattern
dominated by a small number of strong head enterprises in the market.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
